American Portfolios Advisors’s SAB Biotherapeutics SABS Stock Holding History

American Portfolios Advisors’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$12.2K	Buy	+1,747	New	+$17.3K	﹤0.01%	2431

Other funds holding SABS

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

IFAM

Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

American Portfolios Advisors's SABS Position: Q3 2022 in Review

American Portfolios Advisors opened a new position in SAB Biotherapeutics (SABS) in Q3 2022: 1,747 shares worth $12.2K. The stake represents ﹤0.01% of the portfolio and ranks #2431 among its holdings.

40 funds tracked by Wall St. Rank hold SABS as of Q3 2022.

American Portfolios Advisors held 1,747 shares of SAB Biotherapeutics worth $12.2K as of Q3 2022.
SAB Biotherapeutics was a new American Portfolios Advisors position in Q3 2022.
SAB Biotherapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #2431 holding.
40 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.